Endometrial Cancer Survivorship Follow-Up Questions

Start with an honest gap. NCI's clinical summary on endometrial cancer treatment has no surveillance schedule in it. NCI publishes no interval for exams, imaging, or blood tests specific to this cancer.

What NCI does publish is a general pattern for cancer survivors. People usually return every 3 to 4 months during the first 2 to 3 years after treatment, then once or twice a year after that.

NCI is clear that this is not a rule. The schedule depends on three things. Those are the type of cancer, the treatment received, and overall health. Any treatment-related problems count too.

So one question fits the first follow-up visit. Where does the proposed schedule come from, and what would change it?

NCI names them separately, and both are worth requesting by name.

A treatment summary is a written record of what was done. The cancer team should provide it. A future doctor will read it to learn the radiation dose, the surgery, and the drugs given.

A follow-up care plan sets out what happens next. It includes advice for care after treatment ends. It may also cover emotional, social, or money needs.

Together they form a survivorship care plan. NCI advises keeping both with your medical records and sharing them with the primary care doctor.

This is the single most useful fact on this page, and it rarely comes up in follow-up visits.

NCI's clinical summary cites published evidence on this point. Cardiovascular disease is the leading cause of death among endometrial cancer patients.

That changes what follow-up should cover. Blood pressure, blood sugar, cholesterol, and weight are not side topics here. For this group, they are the larger risk.

The practical question follows directly: who is tracking those numbers now, and how often?

Radiation after surgery reduces local and regional recurrence. NCI adds two cautions. Improved survival has not been confirmed. And radiation increases toxic effects.

Two randomized trials in stage I disease put numbers on it. Locoregional recurrence ran 3% to 4% with radiation. It ran 12% to 14% without. Median follow-up was 5 to 6 years. Survival did not differ. Side effects rose.

Which radiation was used matters for the long term. PORTEC-2 tested that directly. It enrolled stage I patients who had no lymph node dissection. They were randomized to vaginal brachytherapy or external-beam radiation. At 5 years, four outcomes were the same. Those were vaginal recurrence, locoregional recurrence, progression-free survival, and overall survival. But the brachytherapy group had far fewer gut side effects. Quality of life was better too. That made brachytherapy the preferred option for stage I disease.

Longer follow-up sharpens the point. A Norwegian trial enrolled 568 patients and followed them more than 20 years. Adding external-beam radiation to brachytherapy did not improve overall survival. Median overall survival was 20.5 years versus 20.48 years. Second cancers were more common after external-beam radiation, with a hazard ratio of 1.42. A later analysis looked at women under 60 at registration. In that group, deaths were higher in the external-beam arm.

So ask three things. Which radiation was given? Over which field? At what dose? That answer shapes what to watch for over decades, not months.

Endometrial tumors are now routinely checked for mismatch repair status. It guides drug choices in advanced disease. NCI's summary describes trials that split patients this way. Results differed sharply between the deficient and proficient groups.

That result has a second life in survivorship. A mismatch repair deficient tumor can point toward Lynch syndrome. That affects future cancer risk, and it affects blood relatives. NCI's endometrial summary does not cover screening intervals for it. Instead it points readers to a separate genetics summary.

So the question is simple. Was that testing done? What did it show? Was a referral to genetic counseling made?

Some women reach an endometrial cancer diagnosis after breast cancer treatment. NCI's summary addresses that path directly.

It states that patients receiving tamoxifen who have abnormal uterine bleeding need follow-up examination and biopsy of the endometrial lining. It also notes that the FDA released a boxed warning covering the increase in uterine cancers linked to tamoxifen use.

That makes any bleeding a reason to be seen rather than watched.

NCI's guidance on follow-up visits is specific about what to raise, and it includes things people often leave out:

• Fatigue that interferes with daily life.
• Problems with bladder, bowel, or sexual function.
• Trouble concentrating, or memory changes.
• Trouble sleeping.
• Weight gain or loss.
• Any new medicine, vitamin, herb, or supplement.
• Changes in the family medical history.
• Anxiety, excessive worrying, or depression.

NCI adds a reassurance worth repeating. New symptoms do not always mean the cancer is back. Fear about every ache is normal. Many of these problems have simple fixes.

NCI raises something most survivorship pages skip. Research has shown a gap between doctors. Treatments or tests ordered by one are sometimes never shared with the other.

Its suggestion is concrete. Ask each doctor to send clinic visit notes to the others. That is an extra step for the patient. But it decides whether a primary care doctor knows the radiation field or not.

Some cancer centers run dedicated survivorship clinics. NCI notes that many NCI-Designated Cancer Centers offer one. So do many large community treatment centers. Our page on endometrial cancer covers the disease itself, and our page on fear of recurrence covers the emotional side of this stage.

• National Cancer Institute, Endometrial Cancer Treatment (PDQ) - Health Professional Version, accessed August 6, 2026
• National Cancer Institute, Follow-Up Medical Care, accessed August 6, 2026